

* 林俊彥醫師

所有發表期刊論文 2019/11/5 更新

1. Lin PT, Teng W*, Jeng WJ, Hsieh YC, Hung CF, Huang CH, Lui KW, Chen YC, Lin CC, **Lin CY***, Sheen IS, Lin SM. Add-on sorafenib is beneficial for hepatocellular carcinoma patients with transarterial chemoembolization refractoriness: A real world experience. *Eur J Gastroenterol Hepatol*; (accepted) (corresponding author).
2. Wu CY, Chen CH, **Lin CY**, Feng LY, Lin YC, Wei KC, Huang CY, Fang JY, Chen PY. CCL5 of glioma-associated microglia/macrophages regulates glioma migration and invasion via calcium-dependent matrix metalloproteinase-2. *Neuro Oncol.* (published on-line)
3. Lin PT, Jeng WJ, Hsieh YC, Teng W*, Hung CF, Huang CH, Liu KW, Chen YC, Lin CC, **Lin CY***, Lin SM, Sheen IS. The incidence and predictors of post transarterial chemoembolization variceal bleeding on hepatocellular carcinoma patients. *Journal of the Formosan Medical Association.* (published on-line) (corresponding author).
4. Tsai MC, **Lin CY**, Hung CH, Lu SN, Tung SY, Chien RN, Lin CL, Wang JH, Chen CH, Chang, KC, Hu TH*, Sheen IS*. Evolution of Renal function under directly acting antivirals treatment for chronic hepatitis C: A real world experience. *J Viral Hepat.* 2019. (published on-line)
5. Huang CF, Hung CH, Cheng PN, Bair MJ, Huang YH, Kao JH, Hsu SJ, Lee PL, Chen JJ, Chien RN, Peng CY, **Lin CY**, Hsieh TY, Cheng CH, Dai CY, Huang JF, Chuang WL, Yu ML. An open-label, randomized, active control trial of 8 versus 12 weeks of elbasvir/grazoprevir for treatment-naïve chronic hepatitis C genotype 1b patients with mild fibrosis (EGALITE): Impact of baseline viral loads and NS5A resistance-associated substitution. *J Infect Dis.* 2019 (published on-line)
6. Chen PY, Wu YJ, Fang JH, Chen HC, Feng LY, Huang CY, Wei KC, Fang JY*, **Lin CY***. Functional Change of Effector Tumor-Infiltrating CCR5+CD38+HLA-DR+CD8+ T Cells in glioma microenvironment. *Frontier Immunol.* ; 2019: 10:2395 (corresponding author).
7. Chen PC, Chen BH, Huang CH, Jeng WJ, Hsieh YC, Teng W, Chen YC, Ho YP, Sheen IS, **Lin CY**. Integrated model for end-stage liver disease maybe superior to some

other model for end-stage liver disease-based systems in addition to Child-Turcotte-Pugh and albumin-bilirubin scores in patients with hepatitis B virus-related liver cirrhosis and spontaneous bacterial peritonitis. *Eur J Gastroenterol Hepatol*; 2019; (10):1256-1263

8. Huang CT, Hung CY, Hsieh YC, Velue AB, He YC, Huang YL, Chen TA, Chen TC, Lin CY, Lin YC, Shih SR, Dutta A*. Effect of aloin on viral neuraminidase and hemagglutinin-specific T cell immunity in acute influenza. *Phytomedicine*; 2019; 4; 64:152904
9. Kao JH, Lin CY, Chuang WL, Cheng YY, Hu JY, Liang WK, Friebe P, Palmer S, Huang CS. nical evaluation of IntelliPlex™ HCV genotyping kit for hepatitis C virus genotyping. *Diagn Microbiol Infect Dis*. 2019; 94(4): 344-348.
10. Chen CH, Chen CH, Lin CL, Lin CY, Hu TH, Tung SY, Hsieh SY, Lu SN, Chien RN, Hung CH, Sheen IS. Real-world safety and efficacy of paritaprevir/ritonavir/ombitasvir plus dasabuvir ± ribavirin in patients with hepatitis C virus genotype 1 and advanced hepatic fibrosis or compensated cirrhosis: a multicenter pooled analysis. *Scientific Reports*. 2019 8; 9(1):7086
11. Huang CH, Wu LS, Jeng WJ, Cheng YF, Ko YS, Sheen IS*, Lin CY*. In HCV-related liver cirrhosis, local pulse wave velocity increases and in decompensated patients correlates with poorer survival. *PLoS ONE*, 2019, 14(3), e0212770. (corresponding author)
12. Yu ML, Hung CH, Liu CH, Peng CY, Su CW, Liu CJ, Lin CY, Huang CF, Chen DS, Kao JH, Huang JF, Chen PJ, Cheng PN, Chien RN, Hsu SJ, Chuang WL, Huang YH. Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions. *Journal of the Formosan Medical Association* 2019; 118(2): 556-564.
13. Chen YC, Teng W, Hsieh YC, Chen WT, Jeng WJ*, Huang CH, Lin CC, Chen YC, Lin SM, Lin CY*, Sheen IS. Timely eradication of HCV viremia by PegIFN/RBV is crucial in prevention of post RFA recurrence in CHC-HCC patients. *Journal of the Formosan Medical Association* 2019;118(8):1239-1246. (corresponding author).
14. Huang PH, Kuo CJ*, Lin CW, Cheng YM, Hu HC, Lin CY, Su MY, Chiu CT. Mesalazine-related lung disease in a patient with ulcerative colitis: A case report. *Medicine (Baltimore)*. 2018; 97(48):e13242.

15. Lin YC, Hsu CY, Huang SK, Fan YH, Huang CH, Yang CK, Su WT, Chang PC, Dutta A, Liu YJ, Huang CT, Chen TC, **Lin CY***. Induction of liver-specific intrahepatic myeloid cells aggregation expands CD8 T cell and inhibits growth of murine hepatoma. *Oncoimmunology*, 2018. **7(12)**: p. e1502129 (corresponding author)
16. Hsieh Y-C, Jeng W-J, Huang C-H, Teng W, Chen W-T, Chen Y-C, Lin SM, Tai DI, **Lin CY***, Sheen IS*. Hepatic decompensation during paritaprevir/ritonavir/ombitasvir/dasabuvir treatment for genotype 1b chronic hepatitis C patients with advanced fibrosis and compensated cirrhosis. *PLoS ONE* 2018; **13(8)**: e0202777. (corresponding author)
17. Chen CL, Sua LH, Janapatla RP, **Lin CY***, Chiu CH*. Genetic analysis of virulence and antimicrobial-resistant plasmid pOU7519 in *Salmonella enterica* serovar Choleraesuis. *J Microbiol Immunol Infect.* 2017: S1684-1182(17)30260-8. (corresponding author)
18. Lin CC, Su SH, Jeng WJ, Huang CH, Teng W, Chen WT, Chen YC, **Lin CY***, Sheen IS. CCL4 is the only predictor for non-responder in GT-1 CHC patients with favorable IL28B genotype when treated with PegIFN/RBV. *BMC Gastroenterol.* 2017; **17(1)**:169. (corresponding author)
19. Hu CC, Jeng WJ, Chen YC, Fang JH, Huang CH, Teng W, Hsieh YC, Lin YC, Chien RN, Sheen IS, **Lin CY***. Memory Regulatory T cells Increase Only In Inflammatory Phase of Chronic Hepatitis B Infection and Related to Galectin-9/ Tim-3 interaction. *Scientific Reports.* 2017. **7(1)**: p. 15280 (corresponding author)
20. Lee CH, Wan YL, Hsu TH, Huang SF, Yu MC, Lee WC, Tsui PH, Chen YC, **Lin CY**, Tai DI*. Interpretation US Elastography in Chronic Hepatitis B with or without anti-HBV Therapy. *Applied Sciences.* 2017, **7**, 1164.
21. Tai DI*, Jeng WJ, **Lin CY**. A global perspective on HBV-related SNPs and evolution during human migration. *Hepatology Communications.* 2017; **1**, 1005–1013
22. Teng W, Hsieh YC, Lui KW, Chen WT, Hung CF, Huang CH, Chen YC, Jeng WJ, Lin CC, **Lin CY**, Lin SM, Sheen IS. Eradication of hepatitis C virus profoundly prolongs survival in hepatocellular carcinoma patients receiving transarterial chemoembolization. *J Viral Hepat.* 2017; **24(12)**:1160-1167.
23. Huang CT*, Hung CY, Chen TC, **Lin CY**, Lin YC, Chang CS, He YC, Huang YL, Dutta A. Rapamycin adjuvant and exacerbation of severe influenza in an experimental

- mouse model. *Scientific Reports*. 2017; 7(1):4136
24. Lee MH*, Huang CF, Lai HC, Lin CY, Dai CY, Liu CJ, Wang JH, Huang JF, Su WP, Yang HC, Kee KM, Yeh ML, Chuang PH, Hsu SJ, Huang CI, Kao JT, Chen CC, Chen SH, Jeng WJ, Yang HI, Yuan Y, Lu SN, Sheen IS, Liu CH, Peng CY, Kao JH, Yu ML, Chuang WL, Chen CJ. Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients. *Scientific Reports*. 2017; 7(1):3718.
25. Hsu JT, Hsu CS, Le PH, Chen TC, Chou WC, Lin CY*, Yeh TS*. Immunochemotherapy benefits in gastric cancer patients stratified by programmed death-1 ligand-1. *Journal of Surgical Research*. 2017; 211: 30-9. (corresponding author)
26. Cheng YT, Jeng WJ, Lin CC, Chen WT, Sheen IS, Lin CY, Lin SM*. Percutaneous radiofrequency ablation of tumor feeding artery before target tumor ablation may reduce local tumor progression in hepatocellular carcinoma. *Biomed J*. 2016; 39(6):400-406.
27. Huang CH, Jeng WJ, Ho YP, Teng W, Hsieh YC, We Chen WT, Chen YC, Lin HH, Sheen IS, Lin CY*. Increased EMR2-expressed neutrophils were apoptotic, correlated with infection and predict overall mortality in liver cirrhotic patients. *Scientific Reports*. 2016; 6: 38250 (corresponding author)
28. Dutta A, Huang CT*, Lin CY, Chen TC, Lin YC, Chang CS, He YC. Sterilizing immunity to influenza virus infection requires local antigen-specific T cell response in the lungs. *Sci Rep*. 2016 Sep 6;6:32973. doi: 10.1038/srep32973.
29. Wu CJ, Lu CH, Chen LC, Nguyen DT, Yi-Shu Huang YS, Hsi-Hsien Lin HH, Lin CY, Kuo ML*. CD4 down regulation and raft dissociation by the non-depleting YTS177 antibody hinder murine T helper cell activities. *Biochemical and Biophysical Research Communications (BBRC)*. 2016; 472(4), 973–979
30. Wu CH, Chen TH*, Lin CY, Chiu CH, Su MY, Chiu CT. Analysis of ascitic fluid lactoferrin levels in the diagnosis of spontaneous bacterial peritonitis after systemic antibiotic treatment. *Advances in Digestive Medicine*. 2015; 2 (4), 123–127.
31. Teng W, Chang TC, Huang CH, Jeng WJ, Chen WT, Huang CW, Ho YP, Lin CY*, Sheen IS. IL28B polymorphism and early anemia predict the early null response in

- genotype-1 chronic hepatitis C with dual therapy. *Advances in Digestive Medicine*. 2015; 2 (4), 128–134. (corresponding author)
32. Kang CW, Dutta A, Chang LY, Mahalingam J, Lin YC, Chiang JM, Hsu CY, Huang CT, Su WT, Chu YY, **Lin CY***. Apoptosis of tumor infiltrating effector TIM-3+CD8+ T cells in colon cancer. *Scientific Reports*. 2015; 5: 15659. (corresponding author)
33. Chang LY, Lin YC, Chiang JM, Mahalingam J, Su SH, Huang CT, Chen WT, Huang CH, Jeng WJ, Chen YC, Lin SM, Sheen IS, **Lin CY***. Blockade of TNF- α signaling benefits cancer therapy by suppressing effector regulatory T cell expansion. *Oncoimmunology*, 2015: 4 (10), e1040215 (corresponding author)
34. Chen PY, Hsieh HY, Huang CY, **Lin CY**, Wei KC, Liu HL*. Focused ultrasound-induced blood–brain barrier opening to enhance interleukin-12 delivery for brain tumor immunotherapy: a preclinical feasibility study. *J Transl Med*. 2015; 13: 93.
35. Su YH, Ng KF, Yu MC, Wu TJ, Yeh TS, Lee WC, Lin YS, Hsieh TH, **Lin CY**, Yeh CT, Chen TC*. Impact of Epidermal Growth Factor Receptor Protein and Gene Alteration on Taiwanese Hepatocellular Carcinoma. *J Gastroenterol Hepatol*. 2015; 30(9):1397-40.
36. Wu TS, Wang LC, Liu SC, Hsu TY, **Lin CY**, Feng GJ, Chen JM, Liu HP, Chung IC, Yen TC, Chang YS, Liao SK, Chang C, Chow KP*. EBV oncogene N-LMP1 induces CD4 T-cell-mediated angiogenic blockade in the murine tumor model. *J. Immunol*. 2015; 194 (9):4577-87
37. Huang CH, Jeng WJ, Ho YP, Teng W, Chen WT, Chen YC, Lin SM, Chiu CT, Sheen IS, **Lin CY***. Increased regulatory T cells in patients with liver cirrhosis correlated with hyperbilirubinemia and predict bacterial complications. *J Gastroenterol Hepatol*. 2015 (30) 775–783. (corresponding author)
38. Dutta A, Huang CT*, Chen TC, **Lin CY**, Chiu CH, Lin YC, Chang CS, and He YC. IL-10 inhibits neuraminidase activated-TGF- β and facilitates Th1 phenotype during early phase of infection. *Nature Communication* 2015; 6:6374
39. Teng W, Jeng WJ, Lin CC, Chen WT, Sheen IS, **Lin CY**, Lin SM*. Insufficient ablative margin determined by early computed tomography may predict the recurrence of hepatocellular carcinoma after radiofrequency ablation. *Liver Cancer* 2015;4: 26–38.
40. Feng Y, Chen CL, Chen TH, Liang YH, Chen HL, **Lin CY**, Chiu CH*. Application of

next-generation sequencing to study ascitic microbiome in cirrhotic patients with or without spontaneous bacterial peritonitis. *J Microbiol Immunol Infect.* 2014; S1684-1182(14) 00161-3.

41. Lin WR, Yen TH, Lim SN, Perng MD, Lin CY, Su MY, Yeh CT, Chiu CT. Granulocyte Colony-Stimulating Factor Reduces Fibrosis in a Mouse Model of Chronic Pancreatitis. *PLoS ONE.* 2014:e116229.
42. Teng W, Chen WT, Ho YP, Jeng WJ*, Huang CH, Chen YC, Lin SM, Chiu CT, Lin CY*, Sheen IS. Predictors of mortality within six weeks after histoacryl injection treatment for gastric variceal bleeding in cirrhotic patients. *Medicine* 2014; 93(29):e321. (corresponding author)
43. Jeng WJ, Lin CC, Chen WT, Sheen IS, Lin CY, Lin SM*. Adjuvant therapy for hepatocellular carcinoma after curative treatment. *Digestive disease* 2014; 32(6):747-54.
44. Mahalingam J, Lin CY, Chiang JM, Su PJ, Chu YY, Lai HY, Fang JH, Huang CT, Lin YC*. CD4+ T cells expressing latency-associated peptide and Foxp3 are an activated subgroup of regulatory T cells enriched in patients with colorectal cancer. *PLoS ONE.* 2014:e108554.
45. Liao MF, Yen SC, Lin CY, Lu RK*. Delayed Liver Function Impairment Secondary to Interferon β -1a Use in Multiple Sclerosis. *Case Rep Neurol.* 2013; 5(2):130-4.
46. Lin CY*, Sheen IS, Chen JY, Huang CW, Huang CH, Jeng WJ, Chen WT. Various Predictors on Sustained Virologic Response in Different Age Groups of Patients with Genotype-1 Chronic Hepatitis C. *J. Clin Gastroenterol.* 2013; 47: 794–799. (corresponding author) .
47. Dutta A, Miaw SC, Yu JS, Chen TC, Lin CY, Lin YC, Chang CS, He YC, Chuang SH, Yen MI, Huang CT*. Altered T-bet Dominance in IFN- Decoupled CD4+ T Cells with Attenuated Cytokine Storm and Preserved Memory in Influenza. *J. Immunol:* 2013; 190(8):4205-14.
48. Lin CY*, Sheen IS, Jeng WJ, Huang CW, Huang CH, Chen JY. Patients younger than forty years old with hepatitis C virus genotype-1 chronic infection had treatment responses similar to genotype-2 infection and not related to interleukin-28B polymorphism. *Annals Hepatol.* 2013; 12(1):62-9 (corresponding author)
49. Lin YC, Mahalingam J, Chiang JM, Su PJ, Chu YY, Lai HY, Fang JH, Huang CT, Chiu CT,

- Lin CY***. Activated but not resting regulatory T cells accumulated in tumor microenvironment and correlated with tumor progression in patients with colorectal cancer. *Int. J. Cancer*; 2013; 132(6):1341-50 (corresponding author)
50. Hu CC, Lin CL, Kuo YL, Chien CH, Chen SW, Yen CL, **Lin CY**, Chien RN*. Efficacy and safety of ribavirin plus pegylated interferon alfa in geriatric patients with chronic hepatitis C. *Aliment Pharmacol Ther*. 2013; 37 (1): 81-90.
51. Wallace C, Yen CH, Yang HC, **Lin CY**, Wu RC, Huang WC, Lin JY, Wei FC*. Vascularized composite allograft rejection is delayed by intrajejunal treatment with donor splenocytes without concomitant immunosuppressants. *Clin Dev Immunol*. 2012;2012:704063.
52. Jeng WJ, **Lin CY**, Chen JY, Huang CH, Huang CW, Sheen IS*. None of the Six SNPs of IL28B Could Predict Treatment Responses in Genotype 2 Chronic HCV Infected Patients by Propensity Score Matching Analysis. *PLoS ONE*. 2012; 7(11):e48217.
53. Liu HL, Hsieh HY, Lu LA, Kang CW, Wu MF, **Lin CY***. Low-Pressure Pulsed Focused Ultrasound with Microbubbles Promotes an Anticancer Immunological Response. *Journal of Translational Medicine*. 2012; 10(1): 221
54. Mahalingam J, Lin YC, Chiang JM, Su PJ, Chu YY, Lai HY, Fang JH, Huang CT, Chiu CT, **Lin CY***. LAP⁺CD4⁺ T cells are suppressors accumulated in the tumor sites and associated with the progression of colorectal cancer. *Clinical Cancer Research*. 2012;18(19); 1–10 (corresponding author)
55. Cheng JC, Yeh YJ, Huang YH, Liang KH, Chang ML, **Lin CY**, Yeh CT*. Hepatic expression of MxA and OAS1 in an ex vivo liver slice assay independently predicts treatment outcomes in chronic hepatitis C. *J Viral Hepat* 2012;19(2):e154-e62.
56. Chang LY, Lin YC, Kan CW, Hsu CY, Chu YY, Huang CT, Day YJ, Chen TC, Yeh CT, **Lin CY***. The indispensable role of CCR5 for in vivo suppressor function of CD103⁺ effector/memory regulatory T cells. *J. Immunol*; 2012; 189(2): 567-74 (corresponding author)
57. Chang LY, Lin YC, Mahalingam J, Huang CT, Chen TW, Kang CW, Peng WM, Chu YY, Chiang JM, Dutta A, Day YJ, Chen TC, Yeh CT, **Lin CY***. Tumor-derived chemokine CCL5 enhances TGF- β mediated killing of CD8⁺ T cells in colon cancer by T regulatory cells. *Cancer Research*. 2012; 72: 1092-1102. (corresponding author)
58. Chen CC, Lin WC, Kong MS, Shi HN, Walker WA, **Lin CY**, Huang CT, Lin YC, Jung SM,

- Lin TZ*. Oral inoculation of probiotics *Lactobacillus acidophilus* NCFM suppresses tumor growth both in segmental orthotopic colon cancer and extraintestinal tissue. *British Journal of Nutrition* 2012;107(11):1623-34.
59. Hu CC, Weng CH, Lin CL, Tien HC, Kuo YL, Chien CH, Yen CL, **Lin CY**, Chien RN*. Predictors of Changes in Hemoglobin Levels in Patients with Chronic Hepatitis C Treated with Ribavirin Plus Pegylated Interferon- α . *Ren Fail* 2012; 34(4):429-34.
60. Chen TY, Hwang TL, **Lin CY**, Lin TN, Lai HY, Tsai WP, Lin HH*. EMR2 Receptor Ligation Modulates Cytokine Secretion Profiles and Cell Survival of Lipopolysaccharide-treated Neutrophils. *Chang Gung Med J.* 2011; 34: 468-77
61. Huang CH, **Lin CY**, Sheen IS, Chiu CT, Ho YP*. A Comparison of Child-Turcotte-Pugh Classification with Four Models of End-Stage Liver-Based Prognostic System For Spontaneous Bacterial Peritonitis in Cirrhosis. *Chinese Journal of Gastroenterology.* 2011; 28: 15-23.
62. **Lin CY**, Chen JY, Lin TN, Jeng WJ, Huang CH, Huang CW, Chang SW, Sheen IS*. IL28B SNP rs12979860 Is a Critical Predictor for On-Treatment and Sustained Virologic Response in Patients with Hepatitis C Virus Genotype-1 Infection. *PLoS ONE*; 2011; 6(3): e18322.
63. Chen JY, **Lin CY**, Wang CM, Lin YT, Kuo SN, Shiu CF, Chang SW, Wu J, Sheen IS*. IL28B genetic variations are associated with Sustained virological response of Interferon- α plus Ribavirin therapy in Taiwanese chronic HCV infection. *Genes and Immunity.* 2011;12(4):300-9.
64. Chen WT, **Lin CY**, Sheen IS, Huang CW, Lin TN, Lin CJ, Jeng WJ, Huang CH, Ho YP*, Chiu CT. MELD score is an Easy and Powerful Predictor for Early Mortality in Patients with Re-bleeding after Endoscopic Band Ligation for Variceal Bleeding. *World Journal of Gastroenterology*; 2011; 17(16): 2120-2125.
65. Huang CH, **Lin CY**, Sheen IS, Chen WT, Lin TN, Ho YP, Chiu CT. Recurrence of SBP in Cirrhotic Patients Non-prophylactically Treated with Norfloxacin: Serum Albumin as an Easy but Reliable Predictive Factor. *Liver International.* 2011; 31(2):184-91.
66. Ho YP, Chiu CT, Sheen IS, Tseng SC, Lai PC, Ho SY, Chen WT, Lin TN, **Lin CY***. Tumor Necrosis Factor- α and Interleukin-10 Contribute to Immunoparalysis in Patients with Acute Pancreatitis. *Hum Immunol* 2011; 72(1):18-23. (corresponding author)
67. Yeh CT*, So M, Ng J, Yang HW, Chang ML, Lai MW, Chen TC, **Lin CY**, Yeh TS, Lee

- WC. Hepatitis B virus-DNA level and basal core promoter A1762T/G1764A mutation in liver tissue independently predict postoperative survival in hepatocellular carcinoma. *Hepatology* 2010;52(6):1922-33.
68. Ulusal BG, Ulusal AE, Wei FC*, **Lin CY**. Allograft Mass as a Possible Contributing Factor to the Skin Transplant Outcome. *J Surg Res* 2010, 161:321-327.
69. Yeh CT*, Kuo CJ, Lai MW, Chen TC, **Lin CY**, Yeh TS, Lee WC. CD133-positive hepatocellular carcinoma in an area endemic for hepatitis B virus infection. *BMC Cancer*; 2009; 9:324.
70. Chang CJ, Hsu LA, Ko YH, Chen PL, Chuang YT, **Lin CY**, Liao CH, Pang JH*. Thrombin regulates matrix metalloproteinase-9 expression in human monocytes. *Biochem Biophys Res Commun*. 2009; 385:241-6.
71. Lin YC, Chang LY, Huang CT, Peng HM, Chen TC, Yeh CT, **Lin CY***. Effector/memory regulatory T cells lead to the loss of concomitant tumor immunity. *J. Immunol* 2009;182 (10):6095-104. (corresponding author)
72. Lai MW, Huang SF, Lin SM, Chen TC, **Lin CY**, Yeh CN, Yeh TS, Chen MF, Yeh CT*. Expression of the *HCRP1* mRNA in HCC as an independent predictor of disease-free survival after surgical resection. *Hepatology Research*, 2009;39(2):164-76.
73. Yeh CT*, Tang JH, Hsu CW, Chen, Y. C. Chang, M. L, **Lin CY**. Expression of hepatitis B virus nuclear core antigen in young cirrhotic patients is associated with an unfavourable long-term outcome. *J Viral Hepat* 2008;15(11):839-48.
74. Lin WR, Lin DY*, Tai DI, Hsieh SY, **Lin CY**, Sheen IS, Chiu CT. Prevalence of and risk factors for gallbladder polyps detected by ultrasonography among healthy Chinese: Analysis of 34 669 cases. *J Gastroenterol Hepatol*. 2008;23(6):965-9.
75. Tsai IF, **Lin CY***, Huang CT, **Lin CY**, Yang CM, Lin YC, Liao CH. Modulation of human monocyte-derived dendritic cells maturation by a soluble guanylate cyclase activator, YC-1, in a cyclic nucleotide independent manner. *International Immunopharmacology* 2007; 7(10):1299-310. (corresponding author)
76. **Lin CY**, Tsai IF, Ho YP, Huang CT, **Lin CY**, Lin CJ, Tseng SC, Lin WP, Chen WT, Sheen IS*. Endotoxemia Contributes to the Immune Paralysis in Patients with Liver Cirrhosis. *J Hepatol*. 2007;46(5)816-826.
77. **Lin CY**, Tsai MC, Huang CT, Hsu CW, Tseng SC, Tsai IF, Chen YC, Yeh CT, Sheen IS,

- Chien RN*. Liver injury is associated with enhanced regulatory T-cell activity in patients with chronic hepatitis B. *J Viral Hepat* 2007; 14(7):503-11.
78. Chang GW, Davies JQ, Stacey M, Yona S, Bowdish D, Hamann J, Chen TC, **Lin CY**, Gordon S, Lin HH*. CD312, the human adhesion-GPCR EMR2, is differentially expressed during differentiation, maturation, and activation of myeloid cells. *Biochem Biophys Res Commun*. 2007;353(1):133-8.
79. Ho YP, Sheen IS, Chiu CT, Wu CS, **Lin CY***. A strong association between down-regulation of HLA-DR expression and the late mortality in patients with severe acute pancreatitis. *Am J Gastroenterol*; 2006; 101(5): 1117-24. (corresponding author)
80. Chien RN, **Lin CY**, Yeh CT, Liaw YF*. Hepatitis B virus genotype B is associated with better response to thymosin alpha1 therapy than genotype C. *J Viral Hepat*. 2006; 13(12): 845-50.
81. Graca L, Le Moine A, **Lin CY**, Fairchild PJ, Cobbold SP, Waldmann H*. Donor-specific transplantation tolerance: the paradoxical behavior of CD4+CD25+ T cells. *Proc Natl Acad Sci U S A*. 2004; 101(27):10122-6.
82. Cobbold SP, Graca L, **Lin CY**, Adams E, Waldmann H*. Regulatory T cells in the induction and maintenance of peripheral transplantation tolerance. *Transplant International* 2003;16 (2):66-75.
83. **Lin CY**, Graca L, Cobbold SP, Waldmann H*. Dominant transplantation tolerance impairs CD8+T cell function but not expansion. *Nature Immunology* 2002; 3(12): 1208-1213.
84. Graca, L., Thompson, S., **Lin CY**, Adams, E, Cobbold SP, Waldmann H*. Both CD4+CD25+ and CD4+CD25- regulatory cells mediate dominant transplantation tolerance. *J. Immunol*. 2002; 168(11): 5558-5565.
85. Tone M, Tone Y, Babik JM, **Lin CY**, Waldmann H*. The Role of Sp1 and NF-kB in Regulating CD40 Gene Expression. *J Biol Chem*. 2002; 277(11): 8890-7.
86. **Lin CY**, Graca L., Cobbold S., Waldmann H. Approaching tolerance in transplantation. *TransplantLinc*. 2002; 4 (2), pp. 21-30
87. Zelenika D, Adams E, Humm S, **Lin CY**, Waldmann H*, Cobbold SP. The role of CD4+ T-cell subsets in determining transplantation rejection or tolerance. *Immunol Rev* 2001;182: 164-79.

88. Wu CH, Chen FH, Lee CS, **Lin CY**, Chen PC, Wu CS*. Factors affecting detection of bleeding lesion in the stomach by the initial emergency endoscopy. *Chang Gung Medical Journal*. 1997; 20(2); 79-85.
89. **Lin CY**, Lee CS, Lin DY, Hong CF, Wu CS*. Emphysematous Gastritis Secondary to Acute Gastric Dilatation. *J Gastroenterol Hepatol*. 1995; 10; 612-614.
90. Wu CS*, **Lin CY**, Liaw YF. The Role of Helicobacter in the Cirrhotic Patients with Peptic Ulcer. *Gastrointestinal Endoscopy* 1995; 42: 420.
91. **Lin CY**, Chien RN*, Lin PY, Chien PC, Wu CS. Early Gastric Cancer: A Clinicopathological Study. *Chang Gung Medical Journal*. 1994; 11: 102-106.
92. **Lin CY**, Chien RN*, Lin PY, Liaw YF. Hepatic Adenoma: A Case report and Review of Literature. *Chinese Journal of Gastroenterology*. 1994; 11: 28